Adicet Bio (NASDAQ:ACET) 주식

ADICET BIO INC

Adicet Bio

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Adicet Bio Inc

<h3>Gainers</h3>
<ul>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock increased by 79.5% to $0.48 during Friday's pre-market session. The company's market cap stands at $3.0 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) stock increased by 51.0% to $0.83. The market value of their outstanding shares is at $1.9 million. </li>
<li>Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) stock increased by 29.85% to $4.35. The company's market cap stands at $296.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares increased by 24.77% to $1.36. The company's market cap stands at $108.9 million. </li>
<li>Generation Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>) shares increased by 18.62% to $0.43. The company's market cap stands at $28.6 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) stock rose 16.82% to $0.56. The company's market cap stands at $46.2 million. The company's, Q1 earnings came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Jade Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBIO#NASDAQ">JBIO</a>) shares decreased by 44.5% to $5.0 during Friday's pre-market session. The market value of their outstanding shares is at $263.0 million. </li>
<li>Varex Imaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VREX#NASDAQ">VREX</a>) shares declined by 42.2% to $5.0. The company's market cap stands at $206.1 million. As per the press release, Q2 earnings came out yesterday. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares decreased by 41.5% to $0.06. </li>
<li>Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) stock decreased by 35.02% to $2.06. The company's market cap stands at $687.9 million. The company's, Q1 earnings came out yesterday. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares declined by 30.93% to $0.41. The company's market cap stands at $2.7 million. </li>
<li>Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) stock fell 26.65% to $2.12. The market value of their outstanding shares is at $168.5 million. As per the news, the Q1 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ACET

CRVS

CTMX

GBIO

IOVA

JBIO

NCNA

PLRZ

SHPH

VREX

WORX

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) stock moved upwards by 75.2% to $0.96 during Thursday's after-market session. The company's market cap stands at $2.2 million. </li>
<li>Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) stock rose 55.68% to $5.2. The company's market cap stands at $354.4 million. The company's, Q1 earnings came out today. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock moved upwards by 25.81% to $0.34. The market value of their outstanding shares is at $2.1 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock rose 19.55% to $2.14. The market value of their outstanding shares is at $51.9 million. </li>
<li>Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) stock rose 12.87% to $0.54. The company's market cap stands at $44.6 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>TransMedics Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) shares moved upwards by 12.62% to $104.97. The market value of their outstanding shares is at $3.5 billion. As per the news, the Q1 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) stock declined by 45.4% to $1.73 during Thursday's after-market session. The market value of their outstanding shares is at $577.7 million. As per the news, the Q1 earnings report came out today. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares fell 44.42% to $0.06. </li>
<li>DocGo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCGO#NASDAQ">DCGO</a>) shares fell 20.61% to $1.85. The market value of their outstanding shares is at $183.3 million. As per the press release, Q1 earnings came out today. </li>
<li>AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>) stock declined by 20.16% to $7.45. The company's market cap stands at $196.9 million. As per the news, the Q1 earnings report came out today. </li>
<li>Organogenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) stock declined by 18.54% to $4.35. The market value of their outstanding shares is at $551.8 million. The company's, Q1 earnings came out today. </li>
<li>Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) stock declined by 17.27% to $59.95. The market value of their outstanding shares is at $8.2 billion. As per the news, the Q1 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSGM

DCGO

GMED

ORGO

RCEL

TMDX

12 Health Care Stocks Moving In Thursday's After-Market Session

WIIM

Adicet Bio shares are tracing lower. The company reported Q1 financial results.

Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.34) by 8.82 percent. This is a 11.43 percent increase over losses of $(0.35) per share from the same period last year.

Earnings

Earnings Beats

News

Adicet Bio Q1 EPS $(0.31) Beats $(0.34) Estimate

Biotech

General

Adicet Bio To Give Oral Presentation For Its Preclinical ADI-270 Data At The American Society Of Gene And Cell Therapy 28th Annual Meeting

<h3>Gainers</h3>
<ul>
<li>Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) shares rose 53.5% to $3.0 during Thursday's after-market session. The company's market cap stands at $93.5 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares increased by 17.85% to $10.43. The market value of their outstanding shares is at $65.8 million. </li>
<li>Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) shares moved upwards by 10.23% to $0.58. The company's market cap stands at $47.9 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) stock moved upwards by 9.02% to $0.11. The company's market cap stands at $1.3 million. </li>
<li>Ernexa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) shares moved upwards by 7.51% to $0.2. The market value of their outstanding shares is at $10.3 million. </li>
<li>X4 Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) shares rose 7.44% to $0.2. The company's market cap stands at $35.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) shares decreased by 13.5% to $1.54 during Thursday's after-market session. The market value of their outstanding shares is at $23.8 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares declined by 9.96% to $1.9. The company's market cap stands at $26.1 million. </li>
<li>Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) shares decreased by 6.97% to $0.8. The company's market cap stands at $60.6 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) shares decreased by 6.03% to $0.39. The market value of their outstanding shares is at $9.8 million. </li>
<li>Soleno Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) shares decreased by 5.69% to $66.0. The market value of their outstanding shares is at $2.8 billion. </li>
<li>Hoth Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) stock decreased by 5.59% to $0.75. The market value of their outstanding shares is at $9.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADGM

CLSD

ERNA

FORA

HOTH

SLNO

SNSE

SXTC

SYRA

XCUR

XFOR

Guggenheim analyst Yatin Suneja reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Buy and maintains $7 price target.

Price Target

Reiteration

Analyst Ratings

Guggenheim Reiterates Buy on Adicet Bio, Maintains $7 Price Target

Citizens Capital Markets analyst Reni Benjamin reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) from Market Perform to Market Perform.

Citizens Capital Markets Reiterates Market Perform on Adicet Bioto Market Perform

HC Wainwright &amp; Co. analyst Edward White reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) from Neutral to Neutral.

HC Wainwright & Co. Reiterates Neutral on Adicet Bioto Neutral

Adicet Bio Reports Poster Presentations Highlighting ADI-270 Data At SITC 2025 Spring Scientific Meeting

Health Care

The FDA Has Granted Fast Track Designation To Adicet Bio's ADI-001 For The Potential Treatment Of Adult Patients With Systemic Sclerosis

JMP Securities analyst Reni Benjamin reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) from Market Perform to Market Perform.

JMP Securities Reiterates Market Perform on Adicet Bioto Market Perform

Adicet Bio shares are trading higher after the company was granted FDA Fast Track designation to ADI-001 for treating refractory systemic lupus erythematosus with extrarenal involvement.

Adicet Bio Secures FDA Fast Track Status For ADI-001 In Treating Refractory Systemic Lupus Erythematosus (SLE) With Extrarenal Involvement

Adicet Bio Says FDA Granted Fast Track Designation To ADI-001 For Potential Treatment Of Adult Patients With Refractory Systemic Lupus Erythematosus With Extrarenal Involvement

Plans To Advance Phase 1 Trial Of ADI-001 Across Six Autoimmune Diseases With Preliminary Lupus Nephritis Data Expected In 1H25 And Additional Cohort Data In 2H25; Enrollment For SLE, SSc, IIM, And SPS To Begin In Q1 2025, AAV Enrollment Expected In 2H25; Reports First Patient Dosed In ADI-270 Phase 1 Trial For Metastatic ccRCC With Preliminary Data Anticipated In 1H25; Company Positioned To Build On Momentum In Autoimmune And On

Adicet Bio Highlights Key 2025 Milestones Following 2024 Progress

Adicet Bio Says First Patient Dosed In The Phase 1 Clinical Trial Evaluating ADI-270 In Patients With Metastatic/Advanced ccRCC

Press Releases

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Appoints Michael Grissinger to the Board of Directors

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

Comments

Adicet Bio

뉴스

파트너 / 기고자

벤징가 글로벌